ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,322.31
0.29%
Dow Jones
39,423.73
-0.62%
US Dollar vs MXN
16.68913
0.15%
Brent Oil
81.575
0.06%
Bitcoin
67,992.07
-1.61%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Synvista Therapeutics, (SYI)

  7. Synvista Therapeutics, (SYI) Noticias

SYI

S.Y. Bancorp (SYI)

Synvista Therapeutics,
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:SYI
FechaHoraFuenteTítuloSímboloCompañía
16/03/200905:00Edgar (US Regulatory)Notice of Effectiveness (EFFECT)AMEX:SYISynvista Therapeutics,
12/03/200912:48Edgar (US Regulatory)Post-Effective Amendment to Registration Statement (POS AM)AMEX:SYISynvista Therapeutics,
12/03/200905:03Edgar (US Regulatory)Post-Effective Amendment to an S-8 filing (S-8 POS)AMEX:SYISynvista Therapeutics,
09/03/200911:25Edgar (US Regulatory)Withdrawal of Registration Statement (RW)AMEX:SYISynvista Therapeutics,
09/03/200911:24Edgar (US Regulatory)-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)AMEX:SYISynvista Therapeutics,
26/02/200912:00Edgar (US Regulatory)Current report filing (8-K)AMEX:SYISynvista Therapeutics,
24/02/200915:15PR Newswire (US)Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSEAMEX:SYI
28/01/200915:00PR Newswire (US)Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business UpdateAMEX:SYI
12/01/200907:30PR Newswire (US)Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for AlagebriumAMEX:SYI
24/12/200812:24PR Newswire (US)Synvista Notified by NYSE Alternext of Continued Listing Standards Non-ComplianceAMEX:SYI
16/12/200807:30PR Newswire (US)Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with DeclineAMEX:SYI
15/12/200807:30PR Newswire (US)Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for PsoriasisAMEX:SYI
03/12/200815:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:SYISynvista Therapeutics,
19/11/200808:43PR Newswire (US)Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test KitAMEX:SYISynvista Therapeutics,
14/11/200814:57Edgar (US Regulatory)Quarterly Report (10-Q)AMEX:SYISynvista Therapeutics,
11/11/200807:30PR Newswire (US)Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA MAMEX:SYISynvista Therapeutics,
10/11/200810:57PR Newswire (US)Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare ConferenceAMEX:SYISynvista Therapeutics,
10/11/200807:30PR Newswire (US)Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the AmeriAMEX:SYISynvista Therapeutics,
24/10/200811:10PR Newswire (US)Synvista Therapeutics to Present at the 2008 BIO Investor ForumAMEX:SYISynvista Therapeutics,
10/10/200815:19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:SYISynvista Therapeutics,
10/10/200815:07PR Newswire (US)Synvista Therapeutics Appoints William Federici to its Board of DirectorsAMEX:SYISynvista Therapeutics,
29/09/200808:03PR Newswire (US)Synvista Therapeutics Receives Approval to Begin Phase 2 Trial of Topical SYI-2074 in PsoriasisAMEX:SYISynvista Therapeutics,
17/09/200812:27PR Newswire (US)Synvista Therapeutics Posts Letter to Stockholders on Web SiteAMEX:SYISynvista Therapeutics,
15/09/200808:15PR Newswire (US)Vista Partners Updates Coverage on Synvista Therapeutics, Inc. (Amex: SYI); Maintains $4.46 Target PriceAMEX:SYISynvista Therapeutics,
11/09/200807:00PR Newswire (US)Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in PatientAMEX:SYISynvista Therapeutics,
14/08/200808:29Edgar (US Regulatory)Synvista Therapeutics, Inc. - Quarterly Report (10-Q)AMEX:SYISynvista Therapeutics,
25/07/200805:04Edgar (US Regulatory)Synvista Therapeutics, Inc. - Current report filing (8-K)AMEX:SYISynvista Therapeutics,
24/07/200810:44Edgar (US Regulatory)Synvista Therapeutics, Inc. - Statement of Changes in Beneficial Ownership (4)AMEX:SYISynvista Therapeutics,
06/06/200812:30PR Newswire (US)Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular DiseAMEX:SYISynvista Therapeutics,
04/06/200811:28Edgar (US Regulatory)Synvista Therapeutics, Inc. - Additional Proxy Soliciting Materials (definitive) (DEFA14A)AMEX:SYISynvista Therapeutics,
 Showing the most relevant articles for your search:AMEX:SYI

Su Consulta Reciente

UNSW
PERIETH
Peri Finance Token
TSXV
TGR
Tiger International Reso...
NYSE
ZTRE
RBB Fund Inc
BIT
S32597
Societe Generale Effekten
TSX
6233
Klass
NASDAQ
SPCB
SuperCom
LSE
LABS
Life Science Reit
EU
XS2443920249
ING Group International ...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados